AHR and breast carcinoma: The same study showed that SR1 and a related AHR antagonist SR2 increase self-renewal capacity of breast cancer stem cells by upregulating LY6E which is a gene not directly involved in self-renewal but that can alter cell cycling and responses to growth factors.